- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04249362
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Limoges, France, 87000
- Research Site
-
Marseille, France, 13009
- Research Site
-
Montpellier, France, 34070
- Research Site
-
Nimes, France, 30029
- Research Site
-
Rouen, France, 76031
- Research Site
-
-
-
-
-
Brescia, Italy, 25100
- Research Site
-
Firenze, Italy, 50134
- Research Site
-
Genova, Italy, 16132
- Research Site
-
Meldola, Italy, 47014
- Research Site
-
Messina, Italy, 98158
- Research Site
-
Modena, Italy, 41124
- Research Site
-
Monza, Italy, 20900
- Research Site
-
Negrar, Italy, 37024
- Research Site
-
Pavia, Italy, 27100
- Research Site
-
Pisa, Italy, 56124
- Research Site
-
Ravenna, Italy, 48121
- Research Site
-
Roma, Italy, 00128
- Research Site
-
-
-
-
-
Białystok, Poland, 15-044
- Research Site
-
Gdańsk, Poland, 80-214
- Research Site
-
Olsztyn, Poland, 10-228
- Research Site
-
Szczecin, Poland, 71-730
- Research Site
-
Warszawa, Poland, 02-781
- Research Site
-
-
-
-
-
St. Petersburg, Russian Federation, 197758
- Research Site
-
St. Petersburg, Russian Federation, 197002
- Research Site
-
Ufa, Russian Federation, 450054
- Research Site
-
-
-
-
-
A Coruña, Spain, 15006
- Research Site
-
Barcelona, Spain, 8035
- Research Site
-
Castello de la Plana, Spain, 12002
- Research Site
-
Madrid, Spain, 28050
- Research Site
-
Oviedo, Spain, 33011
- Research Site
-
Pamplona, Spain, 31008
- Research Site
-
Sabadell(Barcelona), Spain, 08208
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85704
- Research Site
-
-
Florida
-
Tampa, Florida, United States, 33612
- Research Site
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving signed informed consent.
- Age ≥ 18 years at study entry.
- Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
- Deemed ineligible for chemotherapy per Investigator assessment.
- Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
- Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
- Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
- World Health Organization/ECOG performance status of ≤2.
- No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
Patients must have adequate organ and marrow function as defined below:
- Hemoglobin ≥ 9.0 g/dL
- Absolute neutrophil count ≥ 1.0 × 109 /L
- Platelet count ≥ 75 × 109/L
- Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome.
- Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN
- Measured creatinine clearance > 30 mL/min or calculated CL > 30 mL/min as determined by Cockcroft-Gault
- Life expectancy of greater than 12 weeks.
- Body weight greater than 30 kg at study entry and at first study drug administration
Exclusion Criteria:
- Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
- Mixed small cell lung cancer and NSCLC histology.
- History of allogeneic organ transplantation.
- Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
- Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
- History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
- History of leptomeningeal carcinomatosis
- History of active primary immunodeficiency
- Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
- Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab
- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
- Participation in another clinical study with an IP administered in the last 4 weeks.
- Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
- Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
- Patients who refuse chemotherapy by their own decision.
- Involvement in the planning and/or conduct of the study
- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.
- Judgment by the Investigator that the patient should not participate in the study
- Genetics research study (optional):
Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A
Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.
|
All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Other Names:
|
Experimental: Cohort B
Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.
|
All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Grade 3 and Grade 4 possibly-related adverse events (PRAEs)
Time Frame: From screening (day -28) to 6 months from the initiation of durvalumab treatment
|
To assess the safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs
|
From screening (day -28) to 6 months from the initiation of durvalumab treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-free survival (PFS)
Time Frame: From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
|
To assess the efficacy of durvalumab treatment .
PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from investigational product (IP) or receives another anticancer therapy prior to progression
|
From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
|
PFS at 6 months (PFS6)
Time Frame: From the first date of treatment until the date of objective disease progression or death (up to maximum 6 months)
|
To assess the efficacy of durvalumab treatment .
PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
|
From the first date of treatment until the date of objective disease progression or death (up to maximum 6 months)
|
PFS at 12 months (PFS12)
Time Frame: From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
|
To assess the efficacy of durvalumab treatment.
PFS is defined as the time from the first date of treatment until the date of objective disease progression or death regardless of whether the patient withdraws from IP or receives another anticancer therapy prior to progression
|
From the first date of treatment until the date of objective disease progression or death (up to maximum 12 months)
|
Median overall survival (OS)
Time Frame: From the first date of treatment until death due to any cause (up to maximum 12 months)
|
To assess the efficacy of durvalumab treatment.
OS is defined as the time from the first date of treatment until death due to any cause
|
From the first date of treatment until death due to any cause (up to maximum 12 months)
|
OS at 12 months (OS12)
Time Frame: From the first date of treatment until death due to any cause (up to maximum 12 months)
|
To assess the efficacy of durvalumab treatment.
OS is defined as the time from the first date of treatment until death due to any cause
|
From the first date of treatment until death due to any cause (up to maximum 12 months)
|
Objective response rate (ORR)
Time Frame: From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression (up to maximum of 12 months)
|
To assess the efficacy of durvalumab treatment in terms of ORR based on Investigator assessments per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
|
From 8 weeks ±1 week after investigational product (IP) treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression (up to maximum of 12 months)
|
Duration of response (DoR)
Time Frame: From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 48 weeks and q12w ±1 week until disease progression (up to maximum of 12 months)
|
To assess the efficacy of durvalumab treatment in terms of DoR.
DoR is defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression
|
From 8 weeks ±1 week after IP treatment initiation and continue q8w ±1 week through 48 weeks and q12w ±1 week until disease progression (up to maximum of 12 months)
|
Number of participants with lung cancer mortality
Time Frame: From date of treatment start until death due to lung cancer (up to maximum of 12 months)
|
To assess the efficacy of durvalumab treatment in terms of lung cancer mortality
|
From date of treatment start until death due to lung cancer (up to maximum of 12 months)
|
Number of participants with adverse events, serious adverse events, adverse event of special interests, and immune-mediated adverse event
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months)
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months)
|
Number of participants with abnormal physical examinations
Time Frame: At screening
|
To assess the safety and tolerability profile of durvalumab treatment
|
At screening
|
Number of participants with abnormal blood pressure
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months
|
Number of participants with abnormal pulse
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months)
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months)
|
Number of participants with abnormal electrocardiograms
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months)
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months)
|
Number of participants with abnormal clinical chemistry
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months)
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months)
|
Number of participants with abnormal hematology
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months
|
Number of participants with abnormal urinalysis
Time Frame: From screening (Day -28) till final visit (up to a maximum of 12 months
|
To assess the safety and tolerability profile of durvalumab treatment
|
From screening (Day -28) till final visit (up to a maximum of 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dr Andrea Riccardo Filippi, Fondazione IRCCS Policlinico San Matteo
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D4194C00009
- 2019-004336-31 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
ETOP IBCSG Partners FoundationAstraZeneca AG SwitzerlandNot yet recruiting
-
AstraZenecaActive, not recruiting
-
Institut Claudius RegaudActive, not recruiting